SPECIAL EDUCATIONAL PROGRAM

Date: 23 October 2025 Time: 7:00–8:00 am

This non-promotional scientific exchange symposium is organised and funded by AstraZeneca for healthcare professionals only.

During this symposium, data may refer to medicines or indications under investigation or that may not be approved in your country. The information should under no circumstances be regarded as a recommendation for use of the medicine or indication. Please consult your local prescribing information. AstraZeneca does not, under any circumstances, promote its products for off-label or unapproved uses

Meeting objectives:

• Examine the current treatment landscape of earlier-stage hepatobiliary cancers and evaluate barriers to optimising outcomes
• Exchange perspectives on the rationale for immunotherapy-based approaches in earlier stages of hepatobiliary cancers
• Explore potential emerging treatment approaches and future considerations in patient management, with a focus on timely diagnosis and the role of the surgeon

Speakers:

• Gonzalo Sapisochin – Spain (Chair)
• Parissa Tabrizian – USA
• Albert Chan – Hong Kong

Agenda

• Welcome and introductions - Gonzalo Sapisochin
• Current management and emerging therapeutic approaches for earlier stages of HCC - Gonzalo Sapisochin
  • Review of clinical management of resectable HCC and evidence gaps in this setting
  • Rationale and key data for immunotherapy-based regimens in earlier stages of HCC, including neoadjuvant, perioperative and downstaging approaches
• Case study discussion: Clinical considerations for the evolving management of resectable HCC - Parissa Tabrizian and all faculty participation
  • Perspectives on potential integration of immunotherapy-based regimens into clinical care of patients with early HCC
  • Discuss considerations for defining recurrence risk in this setting
  • Key considerations for patient selection and MDT-driven decision-making in the context of emerging therapies
• Unmet needs, evidence gaps and perspectives on emerging therapies for early-stage BTC - Albert Chan
  • Overview of current management approaches and remaining unmet needs for resectable BTC
  • Insights on emerging systemic therapies and evaluation of available evidence for immunotherapy-based regimens in early-stage BTC
• Panel discussion: Key considerations for potential future management strategies in resectable BTC - Albert Chan and all faculty participation
  • ​​​​​​​Discussion of potential implications of novel treatment approaches on the clinical management of resectable BTC
  • Perspectives on the evolving role of surgeons in patient management and within the MDT
  • Exploring current limitations and future directions for the timely diagnosis of early-stage BTC, including key considerations for optimising patient care pathways
• Audience Q&A